# Safety Study of High Doses of Zinc in ALS Patients

> **NCT01259050** · PHASE1,PHASE2 · COMPLETED · sponsor: **Phoenix Neurological Associates, LTD** · enrollment: 10 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Zinc and Copper

## Key facts

- **NCT ID:** NCT01259050
- **Lead sponsor:** Phoenix Neurological Associates, LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2012-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259050, "Safety Study of High Doses of Zinc in ALS Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01259050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*